Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) EBIT Margin (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed EBIT Margin for 7 consecutive years, with 17804.21% as the latest value for Q2 2022.

  • On a quarterly basis, EBIT Margin rose 1012619720.0% to 17804.21% in Q2 2022 year-over-year; TTM through Mar 2023 was 58245.64%, a 293451.0% increase, with the full-year FY2025 number at 1407.52%, changed N/A from a year prior.
  • EBIT Margin was 17804.21% for Q2 2022 at Crescent Biopharma, up from 98870.2% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 90.09% in Q1 2020 to a low of 10144001.41% in Q2 2021.
  • A 3-year average of 1286634.42% and a median of 13679.57% in 2020 define the central range for EBIT Margin.
  • Peak YoY movement for EBIT Margin: plummeted -8931525bps in 2021, then soared 1012619720bps in 2022.
  • Crescent Biopharma's EBIT Margin stood at 9554.94% in 2020, then crashed by -935bps to 98870.2% in 2021, then skyrocketed by 82bps to 17804.21% in 2022.
  • Per Business Quant, the three most recent readings for CBIO's EBIT Margin are 17804.21% (Q2 2022), 98870.2% (Q4 2021), and 20028.82% (Q3 2021).